3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 3
1
Phase 2
1
Status
Active not recruiting
3
Recruiting
1
Sponsor Class
OTHER
16
INDUSTRY
4
OTHER_GOV
1
NIH
1
Study Type
Interventional
4
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Low Grade Serous Ovarian Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
604
Carboplatin
374
Paclitaxel
283
Cisplatin
270
Gemcitabine
252
Pemetrexed
194
Bevacizumab
191
Docetaxel
186
Nivolumab
180
Injections
169
Cyclophosphamide
150
atezolizumab
139
Fluorouracil
134
Capecitabine
133
Oxaliplatin
132
Dexamethasone
128
durvalumab
113
Fulvestrant
113
130-nm albumin-bound paclitaxel
110
fludarabine
103
Cetuximab
100
Leucovorin
97
Rituximab
95
venetoclax
90
Lenalidomide
83
enzalutamide
77
Prednisone
77
Azacitidine
74
Irinotecan
73
Doxorubicin
72
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
INDUSTRY
×
defactinib
×
1 year
×
Clear all
NCT06072781
2026-04-02
RAMP 301
Verastem, Inc.
Phase 3
Recruiting
270 enrolled
NCT05074810
2026-01-12
RAMP203
Verastem, Inc.
Phase 1/2
Active not recruiting
153 enrolled
NCT06682572
2025-12-17
RAMP201J
Verastem, Inc.
Phase 2
Active not recruiting
16 enrolled
NCT05669482
2025-09-02
RAMP205
Verastem, Inc.
Phase 1/2
Active not recruiting
40 enrolled